Resource impact statement
No significant resource impact is anticipated
This guideline updates and replaces the NICE guideline on early and locally advanced breast cancer (CG80). This is because new evidence was identified in surveillance that could affect recommendations, and has already changed clinical practice in some locations.
We do not expect this update to the guideline to have a significant impact on resources; that is:
- the resource impact of implementing any single guideline recommendation will be less than £1 million per year in England (or £1,800 per 100,000 population) and
- the resource impact of implementing the whole guideline in England will be less than £5 million per year (or £9,100 per 100,000 population).
This is because we do not think practice will change substantially as a result of this update to the guideline. Where clinical practice does change as a result of this update, there will not be a significant change in resource use.
Clinical commissioning groups commission breast cancer services with the exception of radiotherapy, chemotherapy and some specialist interventions which are commissioned by NHSE. Providers are NHS hospital trusts.
This page was last updated: 18 July 2018